Identifizierung von Biomarkern für die Prognose der Gemcitabin-Therapie beim Pankreaskarzinom: RNA-, DNA- und Immunhistochemische- Analysen
Identification of biomarkers for the prognosis in gemcitabine treated pancreatic cancer: RNA-, DNA- and immunhistochemical- analysis
by Christian Zimmer
Date of Examination:2015-02-11
Date of issue:2015-02-06
Advisor:Prof. Dr. Jürgen Brockmöller
Referee:Prof. Dr. Volker Ellenrieder
Referee:Prof. Dr. Margarete Schön
Files in this item
Name:Dissertation_CZimmer_SUB.pdf
Size:2.31Mb
Format:PDF
Description:Medizinsche Dissertation
Abstract
English
One aim of this study was to investigate the associations of genetic polymorphisms in the genes involved in gemcitabine pathways and the cinical outcome of patients with pancreatic ductal adenocarcinoma. A nucleoitide polymorphism in ENT1 (SLC29A1) gene, a transmembrane transporter of gemcitabine, had an influence on overall survival. Based on immunhistochemical analysis it could be shown, that patients with a high ENT1 protein expression benefits from a gemcitabin therapy.
Keywords: pankreatic cancer; gemcitabin treatment; ent1; genetic polymorphisms; nucleoside transporter
Schlagwörter: Gemcitabin; Pankreaskarzinom; ENT1; genetische Polymorphismen; Nukleosid Transporter